Quantra Coagulation Guide
Interpret Quantra QPlus viscoelastic hemostatic assay results and guide coagulation therapy. Separate fibrinogen contribution (FCS) from platelet contribution (PCS) for targeted hemostatic resuscitation.
Based on: ESC 2022 · ESAIC
Input
Overview
Quantra (HemoSonics) measures blood clot mechanics using ultrasound resonance. Instead of tracking the rotation of pins or cups, Quantra detects how the stiffness of a blood sample changes as the clot forms. This allows the system to measure clot strength directly in physical units (hPa). The QPlus cartridge reports four key parameters: CT (Clotting Time — when clot formation begins), CS (total Clot Stiffness), FCS (Fibrinogen Contribution to Clot Stiffness), and PCS (Platelet Contribution to Clot Stiffness). By separating fibrinogen (FCS) from platelet contribution (PCS), Quantra allows clinicians to identify the dominant cause of weak clot formation and enables goal-directed haemostatic therapy without complex parameter interpretation.
Evidence Summary
Viscoelastic hemostatic assays (VHA) including Quantra have been validated in cardiac surgery and trauma for reducing allogeneic blood product transfusion while maintaining haemostatic safety. Quantra's sonic measurement technology provides real-time clot stiffness profiling. The FCS/PCS separation enables targeted therapy analogous to ROTEM FIBTEM and TEG CFF-MA. Current Quantra-specific evidence is emerging; general VHA evidence (ESA/ESAIC 2023, Class I) supports goal-directed haemostatic management in perioperative settings.